Jump to content

Deracoxib

From Wikipedia, the free encyclopedia
Deracoxib
Ball-and-stick model of the deracoxib molecule
Clinical data
Trade namesDeramaxx
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATCvet code
Legal status
Legal status
  • Veterinary use only
Pharmacokineticdata
Protein bindingHigh (more than 90%)
MetabolismHepatic biotransformation
Eliminationhalf-life3 hours at 2–3 mg/kg
ExcretionIn feces
Identifiers
  • 4-[3-(Difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazole-1-yl] benzenesulfonamide
CAS Number
PubChemCID
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.234.875Edit this at Wikidata
Chemical and physical data
FormulaC17H14F3N3O3S
Molar mass397.37g·mol−1
3D model (JSmol)
  • O=S(=O)(c3ccc(n1nc(cc1c2ccc(OC)c(F)c2)C(F)F)cc3)N
  • InChI=1S/C17H14F3N3O3S/c1-26-16-7-2-10(8-13(16)18)15-9-14(17(19)20)22-23(15)11-3-5-12(6-4-11)27(21,24)25/h2-9,17H,1H3,(H2,21,24,25)checkY
  • Key:WAZQAZKAZLXFMK-UHFFFAOYSA-NcheckY
☒NcheckY(what is this?)(verify)

Deracoxib(trade nameDeramaxx) is anonsteroidal anti-inflammatory drug(NSAID) of thecoxibclass, used in dogs to treat pain associated withosteoarthritis,or to prevent pain following orthopedic or dental surgery. It is available as beef-flavored tablets.[1]

Medical uses[edit]

Deracoxib is used in dogs for the control of pain and inflammation associated with osteoarthritis and for the prevention of pain following orthopedic surgery or dental procedures.[2]

In cats, the use of deracoxib is not recommended.[3]

Contraindications[edit]

Deracoxib is contraindicated for treatment of dogs with hypersensitivity to deracoxib or otherNSAIDs,and dogs with gastro-intestinal ulcers, renal disease, hepatic disorders, hypoproteinemia, dehydration, or cardiac disease.

Dogs with renal disease may need dose adjustment (if the benefits of the medication outweigh the risks), while those on concurrent diuretic therapy are at increased risk for NSAID toxicity and should not be given this medication.

The concurrent use of deracoxib with steroids or other NSAIDs should be avoided. The safety of deracoxib has not been established in pregnant or nursing dogs or in dogs younger than 4 months of age.

Adverse effects[edit]

The most common adverse effects of treatment with deracoxib are vomiting, anorexia, lethargy and depression.[4]Other adverse effects of deracoxib are caused by its effects on thegastrointestinal tract,and include erosions or ulcerations of the lining of the stomach or intestines.[5]

Serious adverse effects, including ulcers which perforate the gastrointestinal tract, have occurred in dogs administered higher than recommended doses of deracoxib, or dogs administered deracoxib at the same time as (or soon after) otherNSAIDsorcorticosteroidmedications.[4]

Documented adverse side effects include serious and sometimes fatal organ system damage or failure.[6]Other side effects include increase in drinking or urination, jaundice, bloody or black stools, pale gums, hot spots, increased respiration (fast or heavy breathing), incoordination, and behavior changes.[citation needed]

Pharmacology[edit]

Deracoxib is a coxib classnonsteroidal anti-inflammatory drug(NSAID).[3]Like other NSAIDs, its effects are caused by inhibition ofcyclooxygenase(COX) enzymes.[7]At the doses used to treat dogs, deracoxib causes greater inhibition ofCOX-2than ofCOX-1,[3]but at doses twice those recommended for use in dogs, deracoxib significantly inhibitsCOX-1as well.[8]

In dogs, thehalf-lifeof deracoxib at the recommended dose is three hours.[8]

Society and culture[edit]

In the U.S., deracoxib was first approved for use in dogs in 2002, under the trade name Deramaxx chewable tablets, sold byNovartis Animal Health.[1]

References[edit]

  1. ^ab"Deramaxx tablets approved by the FDA as the first coxib class drug for veterinary use".dvm360.com. 1 October 2002. Archived fromthe originalon 13 August 2017.Retrieved2017-08-12.
  2. ^Budsberg SC (2015). "Chapter 8: Nonsteroidal anti-inflammatory drugs". In Gaynor JS, Muir WW (eds.).Handbook of Veterinary Pain Management(3rd ed.). Elsevier Mosby. pp. 142–160.ISBN9780323222143.
  3. ^abcKhan SA, McLean MK (March 2012). "Toxicology of frequently encountered nonsteroidal anti-inflammatory drugs in dogs and cats".The Veterinary Clinics of North America. Small Animal Practice.42(2): 289–306, vi–vii.doi:10.1016/j.cvsm.2012.01.003.PMID22381180.
  4. ^abPeterson ME, Talcott PA (2013). "Chapter 65: Nonsteroidal antiinflammatories. Deracoxib".Small animal toxicology(3rd ed.). St. Louis, Mo.: Elsevier. pp. 700–701.ISBN9781455707171.
  5. ^Papich M (2015). "Deracoxib".Saunders Handbook of Veterinary Drugs: Small and Large Animal(4th ed.). Elsevier Health Sciences. p. 211.ISBN9780323244862.
  6. ^"DERAMAXX (deracoxib)"(PDF).Novartis Animal Health US, Inc. Archived fromthe original(PDF)on 2011-04-08.Retrieved2011-06-23.
  7. ^Lees P (2013). "Chapter 19: Analgesic, antiinflammatory, antipyretic drugs". In Riviere JE, Papich M (eds.).Veterinary Pharmacology and Therapeutics(9th ed.). John Wiley & Sons. pp. 457–492.ISBN9781118685907.
  8. ^abHanson PD, Maddison JE (2008). "Chapter 13: Nonsteroidal anti-inflammatory drugs and chondroprotective agents". In Maddison JE, Page SW, Church DB (eds.).Small animal clinical pharmacology(2nd ed.). Edinburgh: Saunders/Elsevier. pp.287–308.ISBN9780702028588.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Deracoxib&oldid=1190950545"